Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4- carboxylic acid hydroxyamide (CP-544439), in rats and dogs: Assessment of the metabolic profile of CP-544439 in plasma and urine of humans

Drug Metabolism and Disposition

Volumn 36, Issue 9, 2008, Pages 1869-1883

  Dalvie, Deepak ^a   Cosker, Theresa ^a   Boyden, Tracey ^a   Zhou, Sue ^a   Schroeder, Clinton ^a   Potchoiba, Michael J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4 FLUOROPHENOXY)BENZENESULFONYLAMINO]TETRAHYDROPYRAN 4 CARBOXYLIC ACID HYDROXYAMIDE; COLLAGENASE 3; CP 544439; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; REDUCTION; WHOLE BODY AUTORADIOLUMINOGRAPHY; WHOLE BODY IMAGING;

ANIMALS; AREA UNDER CURVE; BLOOD PROTEINS; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MATRIX METALLOPROTEINASE 13; MICROSOMES, LIVER; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 50049110249     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022566     Document Type: Article

References (24)

1. Acheampong AA, Chien DS, Lam S, Vekich S, Breau A, Usansky J, Harcourt D, Munk SA, Nguyen H, Garst M, and Tang-Liu D (1996) Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 26:1035-1055.
2. Allan GA, Gedge JI, Nedderman AN, Roffey SJ, Small HF, and Webster R (2006) Pharmacokinetics and metabolism of UK-383367 in rats and dogs: a rationale for long-lived plasma radioactivity. Xenobiotica 36:399-418.
3. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
4. Bauer L and Exner O (1974) Chemistry of hydroxamic acids and N-hydroxyimides. Angew Chemie 86:419-428.
5. Beckett RP, Davidson AH, Drummond AH, Huxley P, and Whittaker MU (1996) Recent advances in matrix metalloproteinase inhibitor research. Drug Discov Today 1:16-26.
6. Beedham C, Bruce SE, Critchley DJ, al-Tayib Y, and Rance DJ (1987) Species variation in hepatic aldehyde oxidase activity. Eur J Drug Metab Pharmacokinet 12:307-310.
7. Conejo-Garcia A and Schofield CJ (2005) A prodrug system for hydroxylamines based on esterase catalysis. Bioorg Med Chem Lett 15:4004-4009.
8. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
9. Hastings KL, El-Hage J, Jacobs A, Leighton J, Morse D, and Osterberg RE (2003) Drug metabolites in safety testing. Toxicol Appl Pharmacol 190:91-92.
10. Honohan T, Fitzpatrick FA, Booth DG, McGrath JP, Morton DR, and Nishizawa EE (1980) Hydrolysis of an orally active platelet inhibitory prostanoid amide in the plasma of several species. Prostaglandins 19:123-136.
11. Kitamura S, Sugihara K, Nakatani K, Ohta S, Ohhara T, Ninomiya S, Green CE, and Tyson CA (1999) Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 48:607-611.
12. Kobashi K, Takebe S, and Hase J (1973) Distribution, metabolism and excretion of caprylo- and nicotinohydroxamic acid. Yakugaku Zasshi 93:1564-1572.
13. Michaelides MR and Curtin ML (1999) Recent advances in matrix metalloproteinase inhibitors research. Curr Pharm Des 5:787-819.
14. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
15. Otterness IG, Bliven ML, Eskra JD, te Koppele JM, Stukenbrok HA, and Milici AJ (2000) Cartilage damage after intraarticular exposure to collagenase 3. Osteoarthritis Cartilage 8:366-373.
16. Potchoiba MJ, Tensfeldt TG, Nocerini MR, and Silber BM (1995) A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography. J Pharmacol Exp Ther 272:953-962.
17. Potchoiba MJ, West M, and Nocerini MR (1998) Quantitative comparison of autoradioluminography and radiometric tissue distribution studies using carbon-14 labeled xenobiotics. Drug Metab Dispos 26:272-277.
18. Prakash C and Soliman V (1997) Metabolism and excretion of a new anxiolytic drug candidate, CP-93393, in Long-Evans rats. Drug Metab Dispos 25:1288-1297.
19. Rao BG (2005) Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 11:295-322.
20. Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, et al. (2004) Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg Med Chem Lett 14:3389-3395.
21. Sugihara K, Kitamura S, and Tatsumi K (1983a) Evidence for reduction of hydroxamic acids to the corresponding amides by liver aldehyde oxidase. Chem Pharm Bull 31:3366-3369.
22. Sugihara K, Kitamura S, and Tatsumi K (1983b) Involvement of liver aldehyde oxidase in conversion of N-hydroxyurethane to urethane. J Pharmacobiodyn 6:677-683.
23. Sugihara K and Tatsumi K (1986) Participation of liver aldehyde oxidase in reductive metabolism of hydroxamic acids to amides. Arch Biochem Biophys 247:289-293.
24. Wang Z, Hop CE, Kim MS, Huskey SE, Baillie TA, and Guan Z (2003) The unanticipated loss of SO2 from sulfonamides in collision-induced dissociation. Rapid Commun Mass Spectrom 17:81-86.